92 related articles for article (PubMed ID: 25263424)
1. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
[TBL] [Abstract][Full Text] [Related]
2. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
[TBL] [Abstract][Full Text] [Related]
3. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
Uttenreuther-Fischer MM; Huang CS; Yu AL
Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
[TBL] [Abstract][Full Text] [Related]
5. Anti-GD2 immunotherapy for neuroblastoma.
Sait S; Modak S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
[TBL] [Abstract][Full Text] [Related]
6. Promising therapeutic targets in neuroblastoma.
Matthay KK; George RE; Yu AL
Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
Perez Horta Z; Goldberg JL; Sondel PM
Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
[TBL] [Abstract][Full Text] [Related]
8. A retrospective investigation of the relationship between neuroblastoma response to anti-GD2 monoclonal antibodies and exposure to opioids for pain management.
Morgan KJ; Dudas A; Furman WL; McCarville MB; Shulkin BL; Lu Z; Darji H; Anghelescu DL
Pediatr Blood Cancer; 2023 Feb; 70(2):e30069. PubMed ID: 36308746
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.
Handgretinger R; Baader P; Dopfer R; Klingebiel T; Reuland P; Treuner J; Reisfeld RA; Niethammer D
Cancer Immunol Immunother; 1992; 35(3):199-204. PubMed ID: 1638557
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
[No Abstract] [Full Text] [Related]
11. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
Cabral J; Fernandez EI; Toy B; Secola R
Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
[TBL] [Abstract][Full Text] [Related]
12. Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastoma.
Unguru Y; Joffe S; Fernandez CV; Yu AL
J Clin Oncol; 2013 Feb; 31(5):641-6. PubMed ID: 23295797
[TBL] [Abstract][Full Text] [Related]
13. WITHDRAWN: Hydromorphone for acute and chronic pain.
Quigley C
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD003447. PubMed ID: 24162935
[TBL] [Abstract][Full Text] [Related]
14. Yoga as a non-pharmacologic therapy to reduce dinutuximab-induced pain in patients with neuroblastoma.
Parisio KN; Kulp T; Heil M; Li Y; Dalton K; McGrath M; Carlowicz C; Donnelly M; Bagatell R; Jubelirer T
Pediatr Blood Cancer; 2024 Apr; 71(4):e30845. PubMed ID: 38192171
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.
Kholodenko IV; Kalinovsky DV; Doronin II; Deyev SM; Kholodenko RV
J Immunol Res; 2018; 2018():7394268. PubMed ID: 30116755
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
Trovillion EM; Michael M; Jordan CC; Brown L; Phillips K; Oesterheld J; Saulnier-Sholler G
Cancer Med; 2024 Feb; 13(3):e7045. PubMed ID: 38396377
[TBL] [Abstract][Full Text] [Related]
17. Acute low back pain as infusion-related reaction to monoclonal antibodies.
Majenka P; Loquai C; Schöning T; Enk A; Hassel J
Front Oncol; 2023; 13():1161818. PubMed ID: 37941549
[TBL] [Abstract][Full Text] [Related]
18. Dexmedetomidine - A Forgotten Adjunct for Myocardial Protection.
Abraham AS; Abraham MS; Abraham JL; Samuel A
Ann Card Anaesth; 2024 Apr; 27(2):179-180. PubMed ID: 38607887
[No Abstract] [Full Text] [Related]
19. Management of Immunotherapy Infusion Reactions.
Peterson C
Clin J Oncol Nurs; 2023 Mar; 27(2):123-128. PubMed ID: 37677832
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy, a new approach for the treatment of human pain.
Goode DJ
Pain; 2024 Apr; 165(4):725-726. PubMed ID: 37975869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
